Showing 5171-5180 of 5644 results for "".
- Eye Cancer Researchers at Bascom Palmer and Sylvester Identify Function of Key Tumor Suppressorhttps://modernod.com/news/eye-cancer-researchers-at-bascom-palmer-and-sylvester-identify-function-of-key-tumor-suppressor/2476900/Cancer cells remember things they shouldn’t. During development, stem and progenitor cells move freely through the body as they differentiate into heart, brain, liver, and eyes. But after humans are born, that process should stop. Cells shouldn’t travel or change anymore; they should stay put and
- Vertical Pharmaceuticals Announces Submission of New Drug Application for RVL-1201https://modernod.com/news/vertical-pharmaceuticals-announces-submission-of-new-drug-application-for-rvl-1201/2476894/Vertical Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced the submission of a new drug application (NDA) to the FDA for approval of RVL-1201 (RVL) for the treatment of acquired blepharoptosis (droopy eyelid). RVL is a novel, once-daily ophthalmic formulation of oxymeta
- RightEye Releases Fully Commercialized Version of EyeQ Trainer Oculomotor Exercise Programhttps://modernod.com/news/righteye-releases-fully-commercialized-version-of-eyeq-trainer-oculomotor-exercise-program/2476892/RightEye has released its fully commercialized version of EyeQ Trainer, an oculomotor exercise program. Paired with its suite of EyeQ Tests, RightEye now offers a complete solution for addressing functional vision impairments faced by millions of Americans. The product will showcase at Vis
- Phase 2 Study Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to AMDhttps://modernod.com/news/phase-2-study-highlights-efficacy-and-safety-data-of-intravitreal-apl-2-for-geographic-atrophy-secondary-to-amd/2476891/Apellis Pharmaceuticals announced details about its phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) have been published in Ophth
- Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Boardhttps://modernod.com/news/oculis-announces-appointment-of-leading-ophthalmology-specialists-to-scientific-advisory-board/2476888/Oculis SA announced the appointments of Eric Donnenfeld, MD, and Pr. Ramin Tadayoni, MD, PhD, to its Scientific Advisory Board (SAB). “I am pleased to welcome Eric and Ramin to our SAB and look forward to their contributions as we focus on our objective of developing topical medicines that
- Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meetinghttps://modernod.com/news/kodiak-sciences-announces-emerging-durability-data-from-ongoing-phase-1b-study-of-ksi-301-in-wet-amd-patients-at-the-retina-society-annual-meeting/2476886/Kodiak Sciences announced emerging durability data in patients with wet age-related macular degeneration (AMD) treated in its phase 1b clinical study of its investigational therapy KSI-301. The results were presented by David M. Brown</
- Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase 3 Study for Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/genentechs-satralizumab-significantly-reduced-relapse-risk-in-second-positive-phase-3-study-for-neuromyelitis-optica-spectrum-disorder/2476875/Genentech presented full pivotal phase 3 study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease. Results from the SAkuraStar study, presented at the 35th Congress of the European Committee for Treatme
- Johnson & Johnson Vision to Launch Tecnis Synergy IOL and Showcase Latest Clinical Data at ESCRShttps://modernod.com/news/johnson-johnson-vision-showcases-latest-clinical-data-and-eye-care-solutions-at-escrs-2/2476873/Johnson & Johnson Vision will highlight key clinical data and the latest solutions in its growing portfolio of innovative products designed to improve vision care across generations at the upcoming European Society of Cataract and Refractive Surgeons (ESCRS) 2019 Annual Meeting in Paris, Fran
- MicroPulse Transscleral Laser Therapy Will be Discussed in Various Presentations and Educational Events at ESCRShttps://modernod.com/news/micropulse-transscleral-laser-therapy-will-be-discussed-in-various-presentations-and-educational-events-at-escrs/2476872/Iridex announced that its patented MicroPulse laser therapy will be featured prominently in research presented at the 2019 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Paris, France. MicroPulse Transscleral Laser Therapy (TLT) is a non-incisional, laser-ba
- Rayner Launching RayOne Trifocal Toric at ESCRShttps://modernod.com/news/rayner-launching-rayone-trifocal-toric-at-escrs/2476866/Rayner announced it is launching its RayOne Trifocal Toric fully preloaded IOL at the ESCRS 2019 congress in Paris. With 11% light loss from its patented diffractive design, RayOne Trifocal Toric will give cataract pa